Eledon Pharmaceuticals (NASDAQ:ELDN) Issues Earnings Results

Eledon Pharmaceuticals (NASDAQ:ELDN) released its quarterly earnings data on Tuesday. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02), Zacks reports.

Eledon Pharmaceuticals Stock Performance

Shares of ELDN traded down $0.56 during midday trading on Wednesday, hitting $4.26. 352,524 shares of the stock traded hands, compared to its average volume of 195,346. Eledon Pharmaceuticals has a 1-year low of $1.11 and a 1-year high of $5.54. The firm has a market capitalization of $168.95 million, a PE ratio of -2.09 and a beta of 0.76. The business’s 50 day moving average price is $3.17 and its two-hundred day moving average price is $2.86.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).